UNIVEC announces entry into Transdermal Patch Mark
Post# of 87152
(Total Views: 285)
Posted On: 08/12/2018 12:48:06 AM
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds its own brand of products. The Transdermal patch can be used for different drug delivery systems. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company.”
https://www.otcmarkets.com/stock/UNVC/news/UN...e?id=41371
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds its own brand of products. The Transdermal patch can be used for different drug delivery systems. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company.”
https://www.otcmarkets.com/stock/UNVC/news/UN...e?id=41371
(1)
(0)